RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04722978, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 70 years; sex: women only

    Registered eligibility fields

  2. Histologically confirmed invasive ductal carcinoma, no specific type (NOS)

    Inclusion criterion 2

  3. Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.

    Inclusion criterion 1

  4. Neutrophil-to-lymphocyte ratios (NLR) in peripheral blood ≥ 2.

    Inclusion criterion 6

  5. At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

    Inclusion criterion 5

  6. Definitive breast cancer susceptibility gene (BRCA) mutation, Programmed Cell Death-Ligand 1 (PD-L1) positive, microsatellite instability-high (MSI-H), and mismatch repair deficient (dMMR).

    Exclusion criterion 2

  7. Pregnant or breast feeding.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04722978, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
  • Histologically confirmed invasive ductal carcinoma, no specific type (NOS)
  • ER negative and progesterone receptor (PR) negative (defined as < 1% positive cells by IHC), human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0-1 staining or fluorescent in situ hybridization (FISH) negative).
  • No prior therapy after first recurrence or diagnosis of metastatic disease.
  • At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
  • Neutrophil-to-lymphocyte ratios (NLR) in peripheral blood ≥ 2.
  • Adequate organ function including bone marrow, renal function, hepatic function, and cardiac reserve (Left ventricular ejection fraction (LVEF) by echocardiogram ≥45%).
  • Compliance with the study protocol.
  • Have provided written and signed informed consent.

Exclusion Criteria:

  • Pregnant or breast feeding.
  • Definitive breast cancer susceptibility gene (BRCA) mutation, Programmed Cell Death-Ligand 1 (PD-L1) positive, microsatellite instability-high (MSI-H), and mismatch repair deficient (dMMR).
  • Patients who are receiving or will receive other biological agents or immunotherapy.
  • Uncontrolled medical problems.
  • Evidence of active acute or chronic infection.
  • Hepatic, renal, cardiac, or bone marrow dysfunction as detailed above.
  • Concurrent malignancy or history of other malignancy within the last five years.
  • Known severe hypersensitivity to moxifloxacin
  • Patients were unable or unwilling to comply with program requirements.

Quoted from ClinicalTrials.gov, NCT04722978, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04722978, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04722978